Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 3 studies. This list may not include all unresolved or historical entries.

  • YESCARTARegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • YescartaRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • YESCARTARegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)

Phase Distribution

Phase 2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

completed267%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_2

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

NCT03642626
completedphase_2

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
completed

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

NCT05349201

Clinical Trials (3)

Showing 3 of 3 trials
NCT03642626Phase 2

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active Not Recruiting
NCT04071366Phase 2

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Completed
NCT05349201

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Completed

All 3 trials loaded

Drug Details

Intervention Type
Varies by study
Total Trials
3